All News

The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, according to Xavier Leleu, MD, PhD.

Patients with relapsed/refractory myeloma from lower socioeconomic groups face worse quality of life, even in countries with universal health care, according to Francesco Sparano, MSc, of the Italian-based GIMEMA Foundation.

Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

Reducing the use of oral corticosteroids in patients with severe asthma is a pressing concern due to their associated adverse effects, health care costs, and impact on quality of life.

Long-term CARTITUDE-1 data show ciltacabtagene autoleucel (cilta-cel) may offer lasting remission and survival in relapsed/refractory multiple myeloma, according to Sundar Jagannath, MBBS, of the Icahn School of Medicine at Mount Sinai.

Richard Lafayette, MD, FACP, explains why a REMS program is not required for the endothelin A receptor antagonist and how patients may need to adjust should final ALIGN trial data fail to show a clinical benefit of atrasentan.

Data from 2019 to 2023 show 9.2% of adults with obesity reported cost-related medication adherence.

Model predicts millions of cases, hospitalizations, and deaths if routine childhood vaccination rates decline significantly.

In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.

A model that can estimate the need for pre-exposure prophylaxis (PrEP) in the US can help to clarify use patterns to address HIV in local settings.

Osteoarthritis leads the burden, projected to affect 50% of postmenopausal women by 2045.

Eric Lander, MD, discussed the difficulty that clinicians and pharmacists face in getting insurance coverage for category 2B treatments in the National Comprehensive Cancer Network guidelines, which could affect how patients are treated for cancer.

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.

The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD.

Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.

An analysis of 1.7 million patients shows semaglutide may significantly reduce Alzheimer and vascular dementia risk compared with other diabetes drugs.

The elimination of the program addressing LGBTQ+ individuals on the national suicide hotline makes reaching specialized help harder, says Hannah Wesolowski of the National Alliance on Mental Illness.

Rising grocery prices are forcing most Americans to shift toward ultraprocessed foods, leading to increased health risks and exacerbating existing disparities, particularly among underserved communities.

Lorna Warwick, CEO of the Lymphoma Coalition, highlights findings underscoring the vital role of clinician communication in managing adverse effects and supporting patient confidence in lymphoma and chronic lymphocytic leukemia (CLL) care.

Up to 257 million Americans could benefit from these prior authorization reforms that could have cross-market implications on health care plans administered through commercial insurers, Medicare Advantage, and Medicaid.

From widening racial health disparities and abortion care restrictions to coverage losses, leadership gaps in addressing social needs, and worsening workforce shortages, the urgent need to improve health equity is underscored in the US.

Circulating tumor DNA (ctDNA) testing changes occur nearly every year, making consistent updates to National Comprehensive Cancer Network (NCCN) guidelines important for clinicians to make decisions on the use of these methods of testing, says Eric Lander, MD.

The FDA approved datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) for the treatment of locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) after receipt of EGFR-directed therapy and platinum-based chemotherapy.

This research highlights the key factors, like leadership buy-in, mandatory protocols, and electronic health record workflows, that influence the effective collection of data on sexual orientation and gender identity in outpatient oncology clinics to improve patient-centered care.

Combining physician education with patient previsit activation increases deprescribing of diabetes medications, according to one study.

Widespread noncompliance with federal cost-sharing rules exists, particularly impacting Medicare beneficiaries and patient-preferred prep options, study finds.

Patients can benefit both financially and clinically by enrolling in ongoing clinical trials, said Eric Lander, MD.

The FDA has approved Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free survival in combination therapy.

Lorundrostat shows promise in reducing blood pressure and proteinuria in patients with hypertension and chronic kidney disease (CKD), highlighting its dual-action benefits.

The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.